IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$6.48

Market cap

$1.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.77

Enterprise value

$1.6B

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
The company's equity has shrunk by 147% YoY but it rose by 4.6% QoQ
IRWD's debt has surged by 66% year-on-year but it is down by 3.5% since the previous quarter
The quick ratio has dropped by 98% year-on-year and by 3.8% since the previous quarter
The net income has contracted by 8% from the previous quarter

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
158.96M
Market cap
$1.03B
Enterprise value
$1.6B
Valuations
Price to book (P/B)
N/A
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
Earnings
Revenue
$413.55M
EBIT
-$979.61M
EBITDA
-$977.81M
Free cash flow
$147.91M
Per share
EPS
-$6.77
Free cash flow per share
$0.94
Book value per share
-$2.11
Revenue per share
$2.62
TBVPS
$2.76
Balance sheet
Total assets
$438.82M
Total liabilities
$769.34M
Debt
$690.42M
Equity
-$330.52M
Working capital
-$44.27M
Liquidity
Debt to equity
-2.09
Current ratio
0.82
Quick ratio
0.77
Net debt/EBITDA
-0.58
Margins
EBITDA margin
-236.4%
Gross margin
100%
Net margin
-261%
Operating margin
-240.5%
Efficiency
Return on assets
-206.6%
Return on equity
N/A
Return on invested capital
-116.3%
Return on capital employed
-525.6%
Return on sales
-236.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-5.12%
1 week
-0.15%
1 month
1.57%
1 year
-37.33%
YTD
-43.36%
QTD
-0.61%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$413.55M
Gross profit
$413.55M
Operating income
-$994.51M
Net income
-$1.08B
Gross margin
100%
Net margin
-261%
IRWD's net margin is down by 15% since the previous quarter
IRWD's operating margin is down by 13% since the previous quarter
The net income has contracted by 8% from the previous quarter
IRWD's revenue is down by 7% QoQ

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
The EPS has declined by 5% since the previous quarter
The company's equity has shrunk by 147% YoY but it rose by 4.6% QoQ
IRWD's P/S is 41% below its 5-year quarterly average of 4.2 and 33% below its last 4 quarters average of 3.7
IRWD's revenue is down by 7% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has decreased by 42% QoQ
The return on sales has declined by 17% since the previous quarter
Ironwood Pharmaceuticals's ROIC has decreased by 11% from the previous quarter

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 43% less than the total liabilities
The quick ratio has dropped by 98% year-on-year and by 3.8% since the previous quarter
Ironwood Pharmaceuticals's current ratio has plunged by 98% YoY and by 2.4% from the previous quarter
The company's equity has shrunk by 147% YoY but it rose by 4.6% QoQ
IRWD's debt has surged by 66% year-on-year but it is down by 3.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.